EUVIMEDEUVIMED entdecken
Crossref

Platelet‐Related Gene Signature Predicts Prognosis, Immune Landscape, and Drug Sensitivity in Acute Myeloid Leukemia

Yi Wu, Wanjia Chen, Siqi Gong, Jiajia Wang, Zhimin Zhai

BioFactors · 2026-05 · 52 (3)

DOI: 10.1002/biof.70123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioFactors, online erschienen am 24.06.2026. Verfasst von Yi Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Blood Platelets, Transcriptome, Biomarkers, Tumor. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Research Fund of Clinical and Translational Research Project of Anhui Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) remains challenging to treat due to clinical heterogeneity and a lack of prognostic biomarkers. To address this, we developed a prognostic signature based on platelet‐related genes (PRGs). By analyzing transcriptomic data from TCGA‐LAML, GSE146173, and Beat AML 2.0 cohorts, we identified and validated an 11‐gene signature (PSME2, PPIF, SYTL4, S100A4, CCND3, SMIM15, PARVB, STXBP5, KCNMB1, GABRE, SLC50A1) using LASSO‐Cox regression. This model effectively stratified patients into high‐ and low‐risk groups with distinct survival outcomes ( p < 0.001) and demonstrated high predictive accuracy (1‐/3‐/5‐year AUC: 0.832/0.782/0.880). High‐risk patients exhibited immunosuppressive features, including upregulated immune checkpoints (CD274, CTLA4, HAVCR2, LAG3, PDCD1LG2, PDCD1), prominent monocyte infiltration, and reduced dendritic`11 cell activity. Drug sensitivity analysis suggested gefitinib, zebularine, and simvastatin as potential therapies for high‐risk AML ( p < 0.05). We further validated the signature's prognostic value using qPCR and clinical grouping. Notably, in vitro studies indicated that KCNMB1 facilitates AML progression. In conclusion, our robust PRG‐based model elucidates the link between platelet biology, immune dysregulation, and therapeutic vulnerability in AML, offering clinical utility for risk stratification and treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteBlood PlateletsTranscriptomeBiomarkers, TumorHumansPrognosisFemaleGene Expression ProfilingDrug Resistance, NeoplasmGene Expression Regulation, LeukemicMale

Stichwörter der Autor:innen

AMLdrug sensitivityplatelet‐related genesprognostic signaturetumor microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Center of Hematology Research, Anhui Medical University, Hefei, Anhui, China.
  • Department of Hematology, Tongling People's Hospital, Tongling, Anhui, China.

Förderung

  • Research Fund of Clinical and Translational Research Project of Anhui Province

Zitieren

APA

Wu, Y., Chen, W., Gong, S., Wang, J., & Zhai, Z. (2026). Platelet‐Related Gene Signature Predicts Prognosis, Immune Landscape, and Drug Sensitivity in Acute Myeloid Leukemia. BioFactors, 52(3). https://doi.org/10.1002/biof.70123

Vancouver

Wu Y, Chen W, Gong S, Wang J, Zhai Z. Platelet‐Related Gene Signature Predicts Prognosis, Immune Landscape, and Drug Sensitivity in Acute Myeloid Leukemia. BioFactors. 2026;52(3). doi:10.1002/biof.70123

BibTeX
@article{Wu2026,
  author = {Wu, Yi and Chen, Wanjia and Gong, Siqi and Wang, Jiajia and Zhai, Zhimin},
  title = {Platelet‐Related Gene Signature Predicts Prognosis, Immune Landscape, and Drug Sensitivity in Acute Myeloid Leukemia},
  journal = {BioFactors},
  year = {2026},
  volume = {52},
  number = {3},
  doi = {10.1002/biof.70123}
}
Kostenlos starten →